CA3193443A1 - Compositions vaccinales pour reponse immunitaire muqueuse - Google Patents
Compositions vaccinales pour reponse immunitaire muqueuseInfo
- Publication number
- CA3193443A1 CA3193443A1 CA3193443A CA3193443A CA3193443A1 CA 3193443 A1 CA3193443 A1 CA 3193443A1 CA 3193443 A CA3193443 A CA 3193443A CA 3193443 A CA3193443 A CA 3193443A CA 3193443 A1 CA3193443 A1 CA 3193443A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- dosage form
- protein
- solid dosage
- aragonite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des compositions vaccinales qui comprennent un vecteur d'expression à base d'adénovirus lyophilisé et un composé stabilisant, tel que l'aragonite. L'invention concerne en outre des compositions qui comprennent une forme posologique solide constituée d'aragonite pour charger et administrer une composition vaccinale.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/082,907 | 2020-09-24 | ||
US202063104770P | 2020-10-23 | 2020-10-23 | |
US63/104,770 | 2020-10-23 | ||
PCT/US2021/056184 WO2022067273A1 (fr) | 2020-09-24 | 2021-10-22 | Compositions vaccinales pour réponse immunitaire muqueuse |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3193443A1 true CA3193443A1 (fr) | 2022-03-31 |
Family
ID=85685066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3193443A Pending CA3193443A1 (fr) | 2020-09-24 | 2021-10-22 | Compositions vaccinales pour reponse immunitaire muqueuse |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20230113532A (fr) |
CN (1) | CN116348134A (fr) |
CA (1) | CA3193443A1 (fr) |
-
2021
- 2021-10-22 KR KR1020237013330A patent/KR20230113532A/ko unknown
- 2021-10-22 CN CN202180065315.2A patent/CN116348134A/zh active Pending
- 2021-10-22 CA CA3193443A patent/CA3193443A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230113532A (ko) | 2023-07-31 |
CN116348134A (zh) | 2023-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5474720B2 (ja) | ワクチン | |
KR101900460B1 (ko) | 인간 엔테로바이러스에 대한 백신 | |
UA127829C2 (uk) | Стабільна ліофілізована імуногенна композиція, яка містить живий атенуйований рекомбінантний флавівірус, спосіб і набір для її отримання та застосування | |
CN117098553A (zh) | 多价载体和相关疫苗组合物 | |
WO2022217966A1 (fr) | Agent de nano-piégeage inhibant le sars-cov -2 | |
US20210308249A1 (en) | Vlp formulations | |
Dowaidar | Gene-free Viral-like particles (VLPs) offer a safer alternative to inactivating or weakening viral strains for traditional vaccines | |
BRPI0615203A2 (pt) | uso de uma cepa de rotavÍrus atenuado do tipo gxpy | |
US20230348935A1 (en) | Vaccine compositions for mucosal immune response | |
CA3193443A1 (fr) | Compositions vaccinales pour reponse immunitaire muqueuse | |
JP2024521598A (ja) | 粘膜免疫応答のためのワクチン組成物 | |
JP5588586B2 (ja) | ワクチン | |
ES2407840T3 (es) | Vacuna de rotavirus | |
TW202120123A (zh) | 類屈公病毒顆粒疫苗及使用其之方法 | |
EP1676586B1 (fr) | Méthodes pour séparer des variants rotavirus et vaccin de rotavirus vivants attenués | |
WO2022253193A1 (fr) | Application d'un peptide de vaccin contre le nouveau coronavirus et préparation de nanoémulsion associée dans la prévention de souches sauvages et mutantes du nouveau coronavirus | |
TW202334404A (zh) | β冠狀病毒減毒株 | |
KR20230146467A (ko) | 재조합 박테리오파지를 포함하는 엔테로바이러스71 감염 예방용 조성물 | |
JP4771948B2 (ja) | Streptococcusagalactiaeのための免疫原性組成物 | |
TWI314581B (en) | Method of extracting virus from cell culture | |
WO2000029018A1 (fr) | Vaccin combine contre l'hepatite a et la rougeole et son procede de preparation | |
CN116457011A (zh) | 用于治疗冠状病毒的疫苗组合物 |